日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα抑制剂和降解剂Inavolisib可利用FGFR2增强PIK3CA突变实体瘤患者和临床前模型的疗效。

Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha

Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.

临床背景决定了转移性前列腺癌中基因组改变与 AR 抑制剂和化疗反应之间的关系

Shah Kalpit, Secrest Matthew H, Zhou Wei, Wang Shu, Canter Dan, Zhang Yuxiang, Jin Dexter, Sokol Ethan, Nowicka Malgorzata, Ang Houle Armande, Metcalfe Ciara, Gendreau Steven, Schröder Carsten, Wongchenko Matthew, Attard Gerhardt

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

一项针对晚期乳腺癌患者的 Ib 期研究,评估 pictilisib (GDC-0941) 联合紫杉醇、加用或不加用贝伐珠单抗或曲妥珠单抗以及联合来曲唑的疗效。

Schöffski, Patrick; Cresta, Sara; Mayer, Ingrid A; Wildiers, Hans; Damian, Silvia; Gendreau, Steven; Rooney, Isabelle; Morrissey, Kari M; Spoerke, Jill M; Ng, Vivian W; Singel, Stina M; Winer, Eric

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer

一项针对雌激素受体阳性乳腺癌患者的II期随机术前机会窗口研究,比较PI3K抑制剂Pictilisib联合阿那曲唑与单用阿那曲唑的疗效

Schmid, Peter; Pinder, Sarah E; Wheatley, Duncan; Macaskill, Jane; Zammit, Charles; Hu, Jennifer; Price, Robert; Bundred, Nigel; Hadad, Sirwan; Shia, Alice; Sarker, Shah-Jalal; Lim, Louise; Gazinska, Patrycja; Woodman, Natalie; Korbie, Darren; Trau, Matt; Mainwaring, Paul; Gendreau, Steven; Lackner, Mark R; Derynck, Mika; Wilson, Timothy R; Butler, Hannah; Earl, Gemma; Parker, Peter; Purushotham, Arnie; Thompson, Alastair

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Pictilisib治疗雌激素受体阳性、芳香化酶抑制剂耐药的晚期或转移性乳腺癌(FERGI):一项随机、双盲、安慰剂对照的II期试验

Krop, Ian E; Mayer, Ingrid A; Ganju, Vinod; Dickler, Maura; Johnston, Stephen; Morales, Serafin; Yardley, Denise A; Melichar, Bohuslav; Forero-Torres, Andres; Lee, Soo Chin; de Boer, Richard; Petrakova, Katarina; Vallentin, Susanne; Perez, Edith A; Piccart, Martine; Ellis, Matthew; Winer, Eric; Gendreau, Steven; Derynck, Mika; Lackner, Mark; Levy, Gallia; Qiu, Jiaheng; He, Jing; Schmid, Peter

Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis

基于新一代测序和单细胞全基因组拷贝数变异分析的染色体不稳定性评估

Greene, Stephanie B; Dago, Angel E; Leitz, Laura J; Wang, Yipeng; Lee, Jerry; Werner, Shannon L; Gendreau, Steven; Patel, Premal; Jia, Shidong; Zhang, Liangxuan; Tucker, Eric K; Malchiodi, Michael; Graf, Ryon P; Dittamore, Ryan; Marrinucci, Dena; Landers, Mark